TAKEDA PHARMACEUTICAL CO LTD — 13F Holdings & Portfolio
CIK 1395064 · latest 13F-HR filed 2025-11-13
TAKEDA PHARMACEUTICAL CO LTD manages $16.4M in 13F-reported U.S. long-equity assets across 9 reported positions as of its 2025-09-30 13F-HR filing. Its largest disclosed positions are OVID (45.67%), EQ (15.94%), OVID (14.15%). Quarter over quarter (versus its 2025-06-30 filing) the fund opened 0 new positions, exited 3, added to 6, and trimmed 1.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$16.4M
Long-equity book
9
Distinct positions
2025-09-30
Filed 2025-11-13
+0 / −3 / ↑6 / ↓1
vs 2025-06-30
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- Ovid Therapeutics, Inc.$7.3M +294.0%
- Equillium, Inc.$2.0M +353.7%
- Shattuck Labs, Inc.$824.1K +201.8%
- Lyell Immunopharma, Inc.$527.5K +144.9%
- Xilio Therapeutics, Inc. (formerly Akrevia Therapeutics)$240.1K +23.9%
Exited Positions
- HilleVax, Inc.$13.4M
- Turnstone Biologics$321.6K
- Third Harmonic Bio, Inc.$200.0K
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Ovid Therapeutics, Inc. | OVID | 690469101 | $7.5M | 45.67% | 5,750,000 | SH |
| 2 | Equillium, Inc. | EQ | 29446K106 | $2.6M | 15.94% | 1,824,977 | SH |
| 3 | Ovid Therapeutics, Inc. | OVID | 690469101 | $2.3M | 14.15% | 1,781,996 | SH |
| 4 | Xilio Therapeutics, Inc. (formerly Akrevia Therapeutics) | XLO | 98422T100 | $1.2M | 7.59% | 1,475,121 | SH |
| 5 | Shattuck Labs, Inc. | STTK | 82024L103 | $1.2M | 7.53% | 515,619 | SH |
| 6 | Lyell Immunopharma, Inc. | LYEL | 55083R104 | $891.4K | 5.45% | 54,887 | SH |
| 7 | American Well Corporation | AMWL | 03044L204 | $478.1K | 2.92% | 77,733 | SH |
| 8 | Rani Therapeutics Holdings, Inc. | RANI | 753018100 | $101.6K | 0.62% | 203,190 | SH |
| 9 | Standard Biotools, Inc. | LAB | 34385P108 | $21.5K | 0.13% | 16,515 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2025-09-30 | 2025-11-13 | $16.4M | 9 | 0001395064-25-000157 |
| 2025-06-30 | 2025-08-08 | $19.6M | 12 | 0001395064-25-000124 |